Category: Biolase Technology Inc.
Revenues for aesthetic medical device companies largely rise during the 2nd quarter, as purchasing and volume growth trend up, according to a MassDevice.com analysis.
The market for aesthetic medical devices gained some ground during the 2nd quarter, a MassDevice.com analysis shows, although healthy sales growth didn't necessarily translate into healthy bottom lines for all comers.
Stryker's plans to cut more than 100 jobs by closing 2 New York manufacturing facilities will begin in September and continue on a rolling basis until the end of the year, just ahead of implementation of the 2.3% medical device tax.
Stryker (NYSE:SYK) is making good on plans to cut more than 100 positions by closing 2 New York manufacturing plants, moves that the company previously attributed to attempts to cut costs ahead of the coming 2.3% medical device tax.
Thoratec and HeartWare will duke it out with "basically equivalent" heart pump technologies; also, venture capitalists look for devices that replace drugs; Biolase boasts a new Nasdaq ticker; plus, a Funding Roundup and analysts' ups and downs.
The European Commission clears Johnson & Johnson's $21.3 billion buyout of orthopedics giant Synthes after J&J agrees to ditch its DePuy trauma operation to Biomet; also, Intuitive Surgical CEO Guthart practices the Buffett rule; Biolase exits Henry Schein deal; SeraCare shareholders OK $81M Linden Capital buyout; Visium boosts stake in Syneron; Derma Sciences closes MedEfficiency buyout; plus, a Funding Roundup and analysts' ups and downs.
Johnson & Johnson's (NYSE:JNJ) move to ditch its DePuy trauma business mollified EuroZone anti-trust regulators enough to win their approval for its $21.3 billion buyout of Synthes Inc.